Amylin family peptides

• US 8,114,958 B2
• Filed: 02/11/2005
• Issued: 02/14/2012
• Est. Priority Date: 02/11/2004
• Status: Expired due to Fees

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Soares, Christopher J., Hanley, Michael R., Lewis, Diana Y., Parkes, David Geoffrey, Jodka, Carolyn M., Prickett, Kathryn S., Ghosh, Soumitra S., Mack, Christine Marie, Lin, Qing
• Primary Examiner(s): Bunner, Bridget E
• Assistant Examiner(s): HOWARD, ZACHARY C
• Application Number:
  US10/589,054
• Publication Number:
  US 20080274952A1
• Time in Patent Office: 2,559 Days
• Field of Search: None
• US Class Current: 530/307
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 5/22 for decreasing, blocking or antagonising the activity of calcitonin
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695

Abstract

The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.

Claims

1. A peptide having at least 92% sequence identity to the amino acid sequence of SEQ ID NO:

137.

2. The peptide of claim 1, wherein the peptide having at least 92% sequence identity comprises the amino acid sequence of SEQ ID NO:

55, 67, 70, 73, 82, 83, 84, 89, 94, 100, 103, 106, 107, 111, 112, 125, 133, or 137.

3. The peptide of claim 1, wherein the peptide is linked to a polyethylene glycol polymer, a polyamino acid, or a fatty acid.

4. A peptide having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

137.

5. The peptide of claim 4, wherein the peptide having at least 95% sequence identity comprises the amino acid sequence of SEQ ID NO:

40, 42, 43, 46, 47, 48, 54, 64, 65, 68, 69, 74, 78, 79, 80, 81, 85, 90, 91, 92, 93, 95, 96, 97, 98, 99, 101, 102, 109, 118, 119, 121, 130, or 137.

6. A peptide having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:

43.

7. The peptide of claim 6, wherein the peptide having at least 95% sequence identity comprises the amino acid sequence of SEQ ID NO:

43 or 137.

8. The peptide of claim 7, wherein the peptide is linked to a polyethylene glycol polymer, a polyamino acid, or a fatty acid.

9. A peptide comprising the amino acid sequence of SEQ ID NO:

137.

10. The peptide of claim 9, wherein the peptide is linked to a polyethylene glycol polymer, a polyamino acid, or a fatty acid.